Exelixis Inc EXEL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
-
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
-
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
-
FDA Extends Review of Exelixis' Zanzalintinib in Colorectal Cancer
-
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
-
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
-
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
-
Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky
Trading Information
- Previous Close Price
- $64.58
- Day Range
- $64.39–65.20
- 52-Week Range
- $35.46–65.12
- Bid/Ask
- $64.66 / $64.82
- Shares Outstanding
- 247.78M
- Market Cap
- $16.05B
- Volume/Avg
- 128,261 / 2M
Key Statistics
- Price/Earnings (Normalized)
- 19.40
- Price/Sales
- 7.17
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 6.97%
Company Profile
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,077
- Website
- https://www.exelixis.com
Valuation
|
Metric
|
EXEL
|
|---|---|
Price/Earnings (Normalized) | 19.40 |
Price/Book Value | 8.72 |
Price/Sales | 7.17 |
Price/Cash Flow | 14.94 |
Price/Earnings
EXEL
Financial Strength
|
Metric
|
EXEL
|
|---|---|
Quick Ratio | 3.21 |
Current Ratio | 3.46 |
Interest Coverage | — |
Quick Ratio
EXEL
Profitability
|
Metric
|
EXEL
|
|---|---|
Return on Assets (Normalized) | 35.25% |
Return on Equity (Normalized) | 46.73% |
Return on Invested Capital (Normalized) | 40.65% |
Return on Assets
EXEL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%#%<@&K | LOCK|R!Vm | $133B | |||
| Moderna Inc
MRNA
| LOCK|&mDV#p> | LOCK|J$ | $98B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|KXN#vV | LOCK|M<MD | $83B | |||
| argenx SE ADR
ARGX
| LOCK|sFJHt# | LOCK|Qm | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|gpL>?g | LOCK|@% | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|KZr^M>W | LOCK|Ht^F | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|J&n&w$pd | LOCK|&%@P | $28B | |||
| Incyte Corp
INCY
| LOCK|<pvJj# | LOCK|g?# | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|F#xKpM | LOCK|<? | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%@tl?>V | LOCK|qQ | $14B |
United States